Search for a command to run...
No recent news available for this stock.
Conference call summary is not available for this stock.
In the Pharmaceuticals & Drugs sector, Smruthi Organics Ltd. significantly underperforms compared to its peers, showing zero growth and profitability metrics. In contrast, companies like Sun Pharmaceutical and Cipla demonstrate strong growth, solid profitability, and attractive valuations, making them sector leaders. Smruthi's financials indicate it is a potential value trap, requiring careful consideration by investors.
Highest revenue growth (YoY: 8.42%) and strong profitability (ROE: 16.13%, EPS: 45.55).
Strong growth (YoY: 13.28%) with solid profitability metrics (ROE: 16.63%, PE: 23.73).
Consistent growth (YoY: 16.54%) with attractive valuation (PE: 15.50) and high ROE (21.76).